drugset / Trial / NCT04619316
Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.
Timeline
- Start
- 2018-02-05
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 75 mg | — |
| Subject | Trametinib | Small molecule | 2 mg | — |